Drugs / Autologous Adipose Derived MSCs
Autologous Adipose Derived MSCs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02145897 | Aug 2014 → Aug 2015 | limb ischemia | Kasiak Research Pvt. Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03279796 | Oct 2018 → Dec 2019 | epicondylitis, rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adipose Derived MSCs | “Autologous Adipose Derived MSCs” NCT02145897 ↗ |
| Known as | Adipose mesenchymal stem cells | “Adipose mesenchymal stem cells will be isolated from adipose tissue, cultured and then transplanted back to the tendon injury site by multiple point injection.” NCT03279796 ↗ |
| Known as | Mesenchymal stem cells | “adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC)” NCT02145897 ↗ |
| Known as | MSC | “adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC)” NCT02145897 ↗ |
| Modality | Cell therapy | “adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC)” NCT02145897 ↗ |
| Route | Intramuscular | “intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly” NCT02145897 ↗ |
| Route | Intravenous | “intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly” NCT02145897 ↗ |